Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Home > Medicine & Health Science textbooks > Medical specialties, branches of medicine > Nuclear medicine > Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations
Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations

Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations


     0     
5
4
3
2
1



Out of Stock


Notify me when this book is in stock
X
About the Book

This dissertation, "Optimizing Treatment Scheme for Stereotatic Treatment With Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations" by Chun-lun, Chan, 陳俊麟, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Objectives: Lung cancer is the leading cause of cancer mortality in the world. Stereotactic Body Radiation Therapy (SBRT) is a novel technique in treatment of inoperable Non-Small Cell Lung Cancer (NSCLC) in which a high dose delivery of 8-30Gy radiation to the lung tumour with one to five fractions precisely, simultaneously, avoiding as much normal tissue as possible. In the present pilot study, lungs were evenly divided into three parts in cranio-caudal direction, namely Upper Lung, Middle Lung and Lower Lung. As different risk organs are adjacent to different parts of lung, the different radiobiological responses in those risk organs have to be considered in treatment. This study is aimed to determine which dose-fractionation scheme is optimal for each spatial group of 6 patients with radiobiological approach in CyberKnife SBRT treatments. The result can act as a preliminary information for large scale study for establishing a NSCLC treatment protocol to benefit patients with better tumour control but less side effect, hence better quality of life after treatment. Material and Methods: 18 NSCLC patients were retrospectively studied and re-planned with CyberKnife treatment planning system. Each spatial group included six patients. Radiobiological factors including Tumour Control Probability (TCP) and Normal Tissue Complication Probability (NTCP) with Biologically Effective Dose (BED) correction in Universal Survival Curve model (USC) were considered in each plan for heart, spinal cord, esophagus and lungs. Seven commonly clinically used dose-fraction schemes were ranked in each spatial group with Uncomplicated Tumour Control Probability scoring approach. Dosimetric parameters according to Task Group 101 of the American Association of Physicists in Medicine: Volume limits in maximum dose and threshold dose for esophagus, rib, heart, lung, spinal cord, ascending and descending aortas, trachea, and bronchus of each plan were also calculated as supporting information. Results: In radiobiological approach, significant NTCPs (6.2% - 98.2%; mean 55.9%) were found in the ipsilateral lung among all schemes. At the upper lung group, a patient was with 7.0% and 5.7% spinal cord NTCPs and another patient was with 70.9% and 78.4% esophageal NTCPs in the schemes of 3x22Gy and 5x15Gy respectively. The NTCPs of contralateral lung and heart in all spatial groups were negligible. The mean TCP values varied between schemes of lowest BED (5x10Gy) and highest BED (3x22Gy) from 94.1% to 100.0% respectively. In dosimetric approach, if high BED scheme (>106Gy) was applied, few patients may develop Grade3+ complications on bronchus in Upper and Middle lung groups; on spinal cord in Upper and Lower lung groups; and on great vessels in Upper lung group. The low BED schemes such as 3x16Gy and 5x10Gy were relatively safe in all groups. Dose-fractionation scheme of 5x10Gy is the best compromise of TCP and NTCP in all Upper Lung Group, Middle Lung Group and Lower Lung Group (pConclusions: By analyzing the NTCPs and TCPs, 5x10Gy is optimal for all lung group patients. The result can be considered as a reference for large sample scale study in future. Subjects: Lungs - Cancer - Rad


Best Sellers


Product Details
  • ISBN-13: 9781361016336
  • Publisher: Open Dissertation Press
  • Publisher Imprint: Open Dissertation Press
  • Height: 279 mm
  • No of Pages: 108
  • Weight: 268 gr
  • ISBN-10: 1361016337
  • Publisher Date: 26 Jan 2017
  • Binding: Paperback
  • Language: English
  • Spine Width: 6 mm
  • Width: 216 mm


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations
Open Dissertation Press -
Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Optimizing Treatment Scheme for Stereotatic Treatment with Cyberknife in Lung Cancer Patients by Analyzing Radiobiological Parameters Determined by Tumour Locations

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    Fresh on the Shelf


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!